Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$435M |
| 2 |
Amazon
AMZN
|
+$334M |
| 3 |
Moderna
MRNA
|
+$53.9M |
| 4 |
Linde
LIN
|
+$44.2M |
| 5 |
DTE Energy
DTE
|
+$43.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 1000 Value ETF
IWD
|
+$63.6M |
| 2 |
Comcast
CMCSA
|
+$39.7M |
| 3 |
Evergy
EVRG
|
+$38.5M |
| 4 |
Public Service Enterprise Group
PEG
|
+$38.4M |
| 5 |
Bio-Techne
TECH
|
+$30.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.37% |
| 2 | Consumer Discretionary | 10.36% |
| 3 | Financials | 7.14% |
| 4 | Industrials | 6.8% |
| 5 | Healthcare | 6.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
801
Kornit Digital
KRNT
$719M
| $1.51M | 0.02% |
12,187
+6,062
| +99% | +$640K |
|
802
Franklin Templeton
BEN
$17.8B
| $1.51M | 0.02% |
+47,176
| New | +$1.53M |
|
|
CNST
803
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $1.51M | 0.02% |
+44,577
| New | +$1.14M |
|
804
Columbus McKinnon
CMCO
$513M
| $1.5M | 0.02% |
31,125
+24,621
| +379% | +$1.26M |
|
805
eHealth
EHTH
$38.4M
| $1.5M | 0.02% |
+25,659
| New | +$1.69M |
|
|
UMPQ
806
DELISTED
Umpqua Holdings Corp
UMPQ
| $1.5M | 0.02% |
81,084
-188,832
| -70% | -$3.51M |
|
807
CALL
International Flavors & Fragrances
IFF
$22.2B
| $1.5M | 0.02% |
+10,000
| New | +$1.44M |
|
808
ABM Industries
ABM
$2.73B
| $1.49M | 0.02% |
+33,651
| New | +$1.69M |
|
809
Clover Health Investments
CLOV
$2.19B
| $1.49M | 0.02% |
111,670
-124,012
| -53% | -$1.22M |
|
810
e.l.f. Beauty
ELF
$6.24B
| $1.48M | 0.02% |
+54,691
| New | +$1.57M |
|
811
Healthpeak Properties
DOC
$14.9B
| $1.48M | 0.02% |
+44,479
| New | +$1.49M |
|
812
Heartland Express
HTLD
$950M
| $1.48M | 0.02% |
86,431
+824
| +1% | +$15.2K |
|
813
Brighthouse Financial
BHF
$2.98B
| $1.46M | 0.02% |
32,148
+19,843
| +161% | +$932K |
|
814
Columbia Financial
CLBK
$1.21B
| $1.46M | 0.02% |
+84,938
| New | +$1.5M |
|
815
Nordson
NDSN
$18.6B
| $1.46M | 0.02% |
6,640
-1,368
| -17% | -$290K |
|
|
Y
816
DELISTED
Alleghany Corp
Y
| $1.46M | 0.02% |
2,181
-2,089
| -49% | -$1.44M |
|
|
JBGS
817
JBG SMITH
JBGS
$741M
| $1.45M | 0.02% |
+45,988
| New | +$1.5M |
|
818
Sprouts Farmers Market
SFM
$8.01B
| $1.45M | 0.02% |
+58,252
| New | +$1.55M |
|
|
OZON
819
DELISTED
Ozon Holdings PLC American Depositary Shares, each ADS representing one ordinary share
OZON
| $1.44M | 0.02% |
24,608
+3,911
| +19% | +$228K |
|
820
TE Connectivity
TEL
$58.3B
| $1.44M | 0.02% |
10,618
-21,632
| -67% | -$2.9M |
|
821
Popular Inc
BPOP
$10.8B
| $1.43M | 0.02% |
19,062
-3,853
| -17% | -$295K |
|
|
AQUA
822
DELISTED
Evoqua Water Technologies Corp. Common Stock
AQUA
| $1.43M | 0.02% |
42,354
-211,986
| -83% | -$6.38M |
|
823
Sally Beauty Holdings
SBH
$1.54B
| $1.43M | 0.02% |
+64,684
| New | +$1.36M |
|
824
Becton Dickinson
BDX
$51.7B
| $1.43M | 0.02% |
6,016
-12,329
| -67% | -$2.96M |
|
|
SI
825
DELISTED
Silvergate Capital Corporation
SI
| $1.43M | 0.02% |
+12,594
| New | +$1.43M |
|
Similar funds
Michael Gelband's Q2 2021 Portfolio in Review
As of Q2 2021, Michael Gelband held 3,092 positions worth $9.04B, up 32% from $6.86B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Michael Gelband deployed $1.88B of net new capital in Q2 2021, opening 1,032 new positions and adding to 581 existing holdings. Its largest new stake was Linde: 151,692 shares worth $43.9M.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 13% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was iShares Russell 1000 Value ETF, an estimated $63.6M trimmed.
- Michael Gelband's largest Q2 2021 buy was Linde: 151,692 shares worth $43.9M.
- Michael Gelband added most to Microsoft in Q2 2021, an estimated $435M increase.
- Michael Gelband's biggest Q2 2021 reduction was iShares Russell 1000 Value ETF, cutting an estimated $63.6M.
- Michael Gelband fully exited Charles River Laboratories in Q2 2021, selling an estimated $27.9M.
- Michael Gelband's ten largest holdings make up 35% of its $9.04B portfolio in Q2 2021.
- Michael Gelband opened 1,032 new positions and closed 820 in Q2 2021.
- Michael Gelband's portfolio value rose 32% quarter-over-quarter to $9.04B.
Based on ExodusPoint Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.